Abbreviated New Drug Application (ANDA)

What it is

Abbreviated New Drug Application (ANDA) is a U.S. FDA route to approve a generic drug by relying on FDA’s prior finding for a Reference Listed Drug (RLD). Instead of full clinical trials, the applicant shows the generic is the same as the RLD and, moreover, performs as expected in the body (FD&C Act §505(j); 21 CFR 314 Subpart C; 21 CFR 320).

Regulatory framework

• Statute: FD&C Act §505(j) (Hatch–Waxman), including patent and exclusivity rules (§505(j)(5)).
• Regulations: 21 CFR 314 Subpart C (e.g., definitions §314.92; content/format §314.94; refusal to approve §314.127; amendments §314.96; supplements §314.97; filing review §314.101); suitability petition §314.93.
• Bioequivalence: 21 CFR 320 (definitions §320.1; requirements §320.21; possible waivers).
• Quality/GMP: 21 CFR 210/211; application QbR/CMC reviewed by OPQ; facility inspections by ORA.
• Labeling sameness: 21 CFR 314.94(a)(8)(iv); REMS where required (21 U.S.C. §355-1).

Key elements

• Same active ingredient(s), dosage form, strength, route, and uses as the RLD (21 CFR 314.92(a)(1)).
• Bioequivalence to the RLD using FDA-accepted methods (21 CFR 320).
• Labeling the same as the RLD except narrow, allowed differences (e.g., firm details) (21 CFR 314.94(a)(8)(iv)).
• Complete CMC: quality, stability, impurities, and controls that meet cGMP (21 CFR 210/211).
• Patent certification (Paragraph I–IV) and exclusivity statements (FD&C Act §505(j)(2)(A)(vii), §505(j)(5)).
• Use of DMFs with Letters of Authorization when needed.

Process — how it works

• Pick the reference: First, select the RLD and reference standard in the Orange Book; then confirm strengths and current labeling.
• Build the dossier: Next, compile eCTD with QbR/CMC, bioequivalence plans and reports, labeling, patent certifications, and any REMS.
• Submit and file: After submission under 21 CFR 314.94, FDA performs a filing review and may Refuse-to-Receive if incomplete (§314.101).
• FDA review and inspection: Meanwhile, FDA reviews BE, labeling, and quality; it may also inspect facilities.
• Decision: Finally, FDA issues approval or tentative approval if patents or exclusivities still block marketing.

Common pitfalls

• Choosing the wrong RLD or reference standard, which then causes strength or labeling mismatches.
• Weak bioequivalence design, analysis, or unjustified biowaiver requests.
• Labeling not aligned with the current RLD or using unapproved differences.
• CMC gaps (e.g., impurities, stability, validation) or sites not ready for inspection.
• Errors in patent certifications or late notices that harm Paragraph IV timing.

Quick checks

• Confirm the latest RLD labeling and strengths before drafting.
• Follow FDA BE guidances; if you deviate, explain why and support with data.
• Verify DMF status and Letters of Authorization; align timelines with suppliers.
• Map patents and exclusivities early to plan for tentative vs final approval.